PhaseBio Pharmaceuticals Inc

-0.07 (-1.82%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)111.29M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.25 Million
Adjusted EPS-$0.60
See more estimates
10-Day MA$3.83
50-Day MA$3.33
200-Day MA$3.57
See more pivots

PhaseBio Pharmaceuticals Inc Stock, NASDAQ:PHAS

1 Great Valley Parkway, Suite 30, Malvern, Pennsylvania 19355
United States of America
Phone: +1.610.981.6500
Number of Employees: 50


PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp on January 10, 2002 and is headquartered in Malvern, PA.